Health
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): Interim results of a randomized, double-blind, controlled, phase 3 trial – MD Linx
MDLinx original journal summary on Vaccines, Internal Medicine from The Lancet
Findings demonstrate the high efficacy of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG), in preventing laboratory-confirmed symptomatic COVID-19 disease in adults….
Continue Reading
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor